Author Archives: Nickholas Bahr

Stockhead – PharmAust’s monepantel drug could be a game-changer for MND/ALS patients, new data shows

Small Caps – PharmAust encouraged by positive monepantel survival rate assessment

Small Caps – PharmAust solidifies leadership team ahead of key Stage 2/3 MPL study

Stockhead – PharmAust puts experienced hands back on its rudder

Stockhead – ‘Outstanding milestone’: FDA grants PharmAust orphan drug designation for monepantel

Small Caps – PharmAust set to transform MND therapy landscape as monepantel receives FDA orphan drug designation

Stockhead – PharmAust plans for pivotal Phase 2/3 trial after key quarter of milestones

Small Caps – PharmAust gears for major clinical milestones in 2024, following strong start and FDA feedback

Small Caps – PharmAust appoints interim CEO as company plans for pivotal Phase 2/3 study